Lipid Nanoparticle–mRNA Vaccines for Infectious Diseases: Making a Potent Platform Predictable

Lipid nanoparticle (LNP)–mRNA vaccines compressed the path from pathogen sequence to licensed product into less than a year and are now approved for three viral diseases (COVID-19, respiratory syncytial virus and seasonal influenza), with more than twenty indications in clinical development. The platform’s potency is no longer in doubt; its predictability is. We argue that progress is now limited by three interfaces that are engineered largely independently: the lipid–RNA interface, which sets encapsulation, internal structure and storage stability; the particle–cell interface, which sets tropism and the efficiency of endosomal escape; and the particle–immune interface, which sets the balance between adjuvanticity and reactogenicity. Quantitative design rules exist for the first interface, remain empirical for the second, and are almost absent for the third, which is why formulation development still proceeds by screening rather than by calculation. We review the molecular design of the mRNA payload and structural antigen selection; the chemistry, manufacture and intracellular trafficking of LNPs; the immunological chain that links innate activation and dendritic-cell cross-presentation to germinal-centre output; and the clinical evidence across COVID-19, respiratory syncytial virus, influenza, cytomegalovirus, HIV, personalised cancer vaccines and other targets. We conclude by identifying the measurements, pharmacopoeial quality attributes and design rules that would make the next generation of LNP–mRNA vaccines predictable rather than empirical.

Authors

Publication Details

Journal
Vaccines
Published
2026-11-19
DOI
https://doi.org/10.3390/vaccines14110998
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Lipid Nanoparticle–mRNA Vaccines for Infectious Diseases: Making a Potent Platform Predictable

Chenlin Xiu, 程宏献, Yunwang Zhao, Baihai Huang et al.
3 links
Vaccines
RNA Interference and Gene Delivery
article

Lipid Nanoparticle–mRNA Vaccines for Infectious Diseases: Making a Potent Platform Predictable

Chenlin Xiu, 程宏献, Yunwang Zhao, Baihai Huang, Xiongxiong Lu, Lei He, Shiyi Zhou
article en

Abstract

Lipid nanoparticle (LNP)–mRNA vaccines compressed the path from pathogen sequence to licensed product into less than a year and are now approved for three viral diseases (COVID-19, respiratory syncytial virus and seasonal influenza), with more than twenty indications in clinical development. The platform’s potency is no longer in doubt; its predictability is. We argue that progress is now limited by three interfaces that are engineered largely independently: the lipid–RNA interface, which sets encapsulation, internal structure and storage stability; the particle–cell interface, which sets tropism and the efficiency of endosomal escape; and the particle–immune interface, which sets the balance between adjuvanticity and reactogenicity. Quantitative design rules exist for the first interface, remain empirical for the second, and are almost absent for the third, which is why formulation development still proceeds by screening rather than by calculation. We review the molecular design of the mRNA payload and structural antigen selection; the chemistry, manufacture and intracellular trafficking of LNPs; the immunological chain that links innate activation and dendritic-cell cross-presentation to germinal-centre output; and the clinical evidence across COVID-19, respiratory syncytial virus, influenza, cytomegalovirus, HIV, personalised cancer vaccines and other targets. We conclude by identifying the measurements, pharmacopoeial quality attributes and design rules that would make the next generation of LNP–mRNA vaccines predictable rather than empirical.

VaccinesVol. 14(11)
Good health and well-being
RNA Interference and Gene Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon